Different ages and symptoms, the dosage of Vitamin A is different.
Adults (18 years and older)
For vitamin A deficiency not involving xerophthalmia, the following has been used: 100,000 IU by mouth or injected into the muscle daily for three days, followed by 50,000 IU daily for two weeks. A maintenance dose of 10,000-20,000 IU daily for two months has been recommended.
For community-based in intervention, 200,000 IU has been taken as a single dose by mouth monthly for six months.
For acute promyelocytic leukemia (treatment), all- trans retinoic acid (Vesanoid? (tretinoin)) has been administered as follows: 45 milligrams per square meter of body surface area daily by mouth, as two evenly divided doses until complete remission; therapy should be discontinued 30 days after the achievement of complete remission or after 90 days of treatment, whichever occurs first.
For HIV, vitamin A (400,000 IU in adults and 50,000 IU in infants) has been given to women and infants by mouth during the postpartum period for two years.
For mortality reduction, 1,333-200,000 IU has been taken by mouth daily or on alternate days for 28 days to 12 years.
For oral leukoplakia, 300,000 IU has been taken by mouth weekly for 12 months or 200,000 IU has been taken by mouth weekly for six months or 1-2 milligrams of 13- cis -retinoic acid per kilogram of body weight has been taken by mouth daily for three months. Topical 0.1% isotretinoin gel three times daily for four months or a topical formulation of 20 milligrams of acitretin daily in a two-layer mucoadhesive tablet has been used.
For retinitis pigmentosa, the National Eye Institute (NEI) recommends that patients with typical forms receive 15,000 IU of supplemental vitamin A palmitate daily under medical supervision.
For tuberculosis, 5,000-200,000 IU has been taken three times by mouth prior to antituberculosis medication.
For UV-induced skin damage, topical all- trans retinoic acid (tretinoin, the acid form of vitamin A), at a concentration of 0.02% or higher, has been used over a period of 4-11 months.
Adults (18 years and older)
For vitamin A deficiency not involving xerophthalmia, the following has been used: 100,000 IU by mouth or injected into the muscle daily for three days, followed by 50,000 IU daily for two weeks. A maintenance dose of 10,000-20,000 IU daily for two months has been recommended.
For community-based in intervention, 200,000 IU has been taken as a single dose by mouth monthly for six months.
For acute promyelocytic leukemia (treatment), all- trans retinoic acid (Vesanoid? (tretinoin)) has been administered as follows: 45 milligrams per square meter of body surface area daily by mouth, as two evenly divided doses until complete remission; therapy should be discontinued 30 days after the achievement of complete remission or after 90 days of treatment, whichever occurs first.
For HIV, vitamin A (400,000 IU in adults and 50,000 IU in infants) has been given to women and infants by mouth during the postpartum period for two years.
For mortality reduction, 1,333-200,000 IU has been taken by mouth daily or on alternate days for 28 days to 12 years.
For oral leukoplakia, 300,000 IU has been taken by mouth weekly for 12 months or 200,000 IU has been taken by mouth weekly for six months or 1-2 milligrams of 13- cis -retinoic acid per kilogram of body weight has been taken by mouth daily for three months. Topical 0.1% isotretinoin gel three times daily for four months or a topical formulation of 20 milligrams of acitretin daily in a two-layer mucoadhesive tablet has been used.
For retinitis pigmentosa, the National Eye Institute (NEI) recommends that patients with typical forms receive 15,000 IU of supplemental vitamin A palmitate daily under medical supervision.
For tuberculosis, 5,000-200,000 IU has been taken three times by mouth prior to antituberculosis medication.
For UV-induced skin damage, topical all- trans retinoic acid (tretinoin, the acid form of vitamin A), at a concentration of 0.02% or higher, has been used over a period of 4-11 months.
Comment